Copy the page URI to the clipboard
Missailidis, Sotiris; Perkins, Alan; Santos-Filho, Sebastião David; de Souza da Fonseca, Adenilson and Bernardo-Filho, Mario
(2008).
DOI: https://doi.org/10.1590/S1516-89132008000700013
Abstract
In the continuous search for earlier diagnosis and improved therapeutic modalities against cancer, based on our constantly increasing knowledge of cancer biology, aptamers hold the promise to expand on current antibody success, but overcoming some of the problems faced with antibodies as therapeutic or delivery agents in cancer. However, as the first aptamer reached the market as an inhibitor against angiogenesis for the treatment of macular degeneration, aptamers have found only limited applications or interest in oncology, and even less as radiopharmaceuticals for diagnostic imaging and targeted radiotherapy of tumours. Yet, the chemistry for the labelling of aptamers and the options to alter their pharmacokinetic properties, to make them suitable for use as radiopharmaceuticals is now available and recent advances in their development can demonstrate that these molecules would make them ideal delivery vehicles for the development of targeted radiopharmaceuticals that could deliver their radiation load with accuracy to the tumour site, offering improved therapeutic properties and reduced side effects.
CORE (COnnecting REpositories)
CORE (COnnecting REpositories)
